Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma

por Sun, Yang, Wirta, David, Murahashi, Wendy, Mathur, Vidhu, Sankaranarayanan, Sethu, Taylor, Lori K., Yednock, Ted, Fong, Donald S., Goldberg, Jeffrey L.
Publicado 2023

Dent disease presenting with nyctalopia and electroretinographic correlates of vitamin A deficiency

por Arnett, Justin J., Li, Alexa, Yassin, Shaden H., Miller, Robin, Taylor, Lori, Carter, Caitlin E., Shayan-Tabrizi, Katayoon, Borooah, Shyamanga
Publicado 2022

Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates

por Grover, Anita, Sankaranarayanan, Sethu, Mathur, Vidhu, Suri, Poojan, Qiu, Haiyan, Andrews-Zwilling, Yaisa, Mease, Kirsten, Taylor, Lori K., Cahir-McFarland, Ellen, Keswani, Sanjay, Yednock, Ted
Publicado 2023